Skip to main
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 7%

Bulls say

HealthEquity Inc. demonstrated strong financial performance, highlighted by a 13% year-over-year increase in custodial revenue and a remarkable adjusted EBITDA margin of 44.0%, reflecting a 466 basis points improvement. The company's cash flow from operations rose by 28.4%, reaching $339.2 million in FY/26, indicating a robust operational efficiency. Furthermore, total HSA assets increased to $36.5 billion, marking a 13.6% year-over-year growth, driven by higher balances per member and increased engagement, underscoring the company's strong position in the health savings sector.

Bears say

HealthEquity Inc. has projected FY/27 revenue of $1.410 billion, representing a modest 7.4% year-over-year increase, which is slightly below previous estimates, indicating potential revenue growth challenges. Additionally, the company's shares have declined by 13% year-to-date and are currently trading at multiples that suggest they are overvalued compared to both its high-growth peers and its historical valuation averages. Concerns surrounding industry competitiveness, regulatory uncertainties, reliance on external suppliers, and the potential impact of evolving healthcare policies further contribute to the negative outlook on HealthEquity's stock performance.

HealthEquity (HQY) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 14 analysts, HealthEquity (HQY) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.